FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common side effects with Tobi Podhaler (seen in more than 1 patient in 10) are haemoptysis (coughing up blood), dyspnoea (difficulty breathing), dysphonia (hoarseness), cough and productive cough (producing mucus), oropharyngeal pain (affecting the mouth and throat) and pyrexia (fever).
Maltese: L-effetti sekondarji l-aktar komuni b'Tobi Podhaler (li dehru f'aktar minn pazjent 1 minn kull 10) huma emopatażi (tlugħ ta' demm mas-sogħla), dispneja (diffikultà fit-teħid tan-nifs), disfonja (ħanqa), sogħla u sogħla produttiva (li tipproduċi l-mukus), uġigħ orofarinġali (li jaffettwa l-ħalq u l-griżmejn) u piressija (deni).
English: Tobi Podhaler is a medicine that contains the active substance tobramycin.
Maltese: Tobi Podhaler huwa mediċina li fiha s-sustanza attiva t-tobramiċina.
English: Because the number of patients with cystic fibrosis and P. aeruginosa bacterial lung infection is low, the disease is considered ‘rare' and Tobi Podhaler was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 March 2003.
Maltese: Minħabba li l-għadd ta' pazjenti bil-fibrożi ċistika u b'infezzjoni pulmonari b'P. aeruginosa huwa baxx, il-marda hija kkunsidrata "rari" u Tobi Podhaler ġie nnominat bħala "mediċina orfni" (mediċina li tintuża fil-mard rari) fis-17 ta' Marzu 2003.
English: Other information about Tobi Podhaler
Maltese: Informazzjoni oħra dwar Tobi Podhaler
English: Tobi Podhaler is used to suppress chronic lung infection caused by bacteria called Pseudomonas aeruginosa in adults and children aged 6 years and over who have cystic fibrosis.
Maltese: Tobi Podhaler jintuża biex irażżan l-infezzjoni pulmonari kronika kkawżata minn batterji msejħa Pseudomonas aeruginosa fl-adulti u t-tfal li jkollhom ‘il fuq minn 6 snin u li jkollhom il-fibrożi ċistika.
English: It is available as capsules (28 mg) containing a dry powder for inhalation using a portable inhaler device.
Maltese: Jiġi f'kapsuli (28 mg) li fihom trab niexef għall-inalazzjoni bl-użu ta' inalatur li jista' jinġarr.
English: The applicant presented data on an existing nebuliser solution containing tobramycin called Tobi.
Maltese: L-applikant ippreżenta data fuq soluzzjoni eżistenti ta' nebulizzatur li fiha t-tobramiċina, imsejħa Tobi.
English: After four weeks of treatment, the patients taking Tobi Podhaler had an improvement in FEV1 of 13.2%, while patients taking placebo had a reduction in FEV1 of around 0.6%.
Maltese: Wara erba' ġimgħat ta' kura, il-pazjenti li kienu qegħdin jieħdu Tobi Podhaler kellhom titjib fl-FEV1 ta' 13.2%, filwaqt li l-pazjenti li kienu qegħdin jieħdu plaċebo kellhom tnaqqis fl-FEV1 ta' madwar 0.6%.
English: Why has Tobi Podhaler been approved?
Maltese: Għaliex ġie approvat Tobi Podhaler?
English: Tobi Podhaler was studied in two main trials in patients who had cystic fibrosis with P. aeruginosa lung infection.
Maltese: Tobi Podhaler ġie studjat f'żewġ provi ewlenin fuq pazjenti li kellhom il-fibrożi ċistika b'infezzjoni pulmonari b'P. aeruginosa.
English: What is the risk associated with Tobi Podhaler?
Maltese: X'inhu r-riskju assoċjat ma' Tobi Podhaler?
English: What is Tobi Podhaler?
Maltese: X'inhu Tobi Podhaler?
English: How has Tobi Podhaler been studied?
Maltese: Kif ġie studjat Tobi Podhaler?
English: Cystic fibrosis is an inherited disease in which there is accumulation of thick mucus in the lungs that allows bacteria to grow more easily causing infections.
Maltese: Fibrożi ċistika hija marda li tintiret fejn ikun hemm akkumulazzjoni ta' mukus oħxon fil-pulmun li tippermetti lill-batterji jikbru aktar faċilment, u dan jikkawża infezzjonijiet.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tobi Podhaler on 20 July 2011.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Tobi Podhaler fl-20 ta' Lulju 2011.
English: Tobramycin is a well-known antibiotic that has been used to treat lung infection in cystic fibrosis patients, available in the form of a solution used with a nebuliser (a machine that changes a solution into an aerosol that the patient can breathe in).
Maltese: It-tobramiċina hija antibijotiku magħruf sew, li ilu jintuża fil-kura ta' infezzjonijiet pulmonari fuq pazjenti bil-fibrożi ċistika, disponibbli fil-forma ta' soluzzjoni użata ma' nebulizzatur (magna li tbiddel soluzzjoni f'ajrusol li l-pazjent jista' jieħu man-nifs).
English: Tobi Podhaler must not be used in people who are hypersensitive (allergic) to tobramycin, any aminoglycoside or any of the other ingredients.
Maltese: Tobi Podhaler ma għandux jintuża f'persuni li jistgħu jkunu ipersensittivi (allerġiċi) għat-tobramiċina, għal xi aminoglikosidi, jew għal kwalunkwe wieħed mill-ingredjenti l-oħra.
English: For the full list of all side effects reported with Tobi Podhaler, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrapportati b'Tobi Podhaler, ara l-fuljett ta' tagħrif.
English: Emtricitabine/Tenofovir disoproxil Mylan is available as tablets (200 mg emtricitabine and 245 mg tenofovir disoproxil).
Maltese: Emtricitabine/Tenofovir disoproxil Mylan jiġi bħala pilloli (200 mg emtriċitabina u 245 mg tenofovir disoprossil).
English: Emtricitabine/Tenofovir disoproxil Mylan received a marketing authorisation valid throughout the EU on 16 December 2016.
Maltese: Emtricitabine/Tenofovir disoproxil Mylan irċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fis-16 ta' Diċembru 2016.
English: Further information on Emtricitabine/Tenofovir disoproxil Mylan can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/emtricitabinetenofovir-disoproxil-mylan.
Maltese: ema.europa.eu/medicines/human/EPAR/emtricitabinetenofovir-disoproxil-mylan.
English: Emtricitabine/Tenofovir disoproxil Mylan contains two active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug' of tenofovir.
Maltese: Emtricitabine/Tenofovir disoproxil Mylan fih żewġ sustanzi attivi: l-emtriċitabina, li hija inibitur nukleosidiku tat-transkrittażi inversa; u t-tenofovir disoprossil li hija “prodroga” tat-tenofovir.
English: Emtricitabine/Tenofovir disoproxil Mylan is an HIV medicine that is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Emtricitabine/Tenofovir disoproxil Mylan huwa mediċina kontra l-HIV li tintuża flimkien ma' minn talinqas mediċina oħra kontra l-HIV għall-kura ta' adulti infettati bil-virus tal-immunodefiċjenza umana tat-tip 1 (HIV-1), virus li jikkawża s-sindromu tal-immunodefiċjenza akkwiżita (AIDS).
English: Other information about Emtricitabine/Tenofovir disoproxil Mylan
Maltese: Informazzjoni oħra dwar Emtricitabine/Tenofovir disoproxil Mylan
English: The company that markets Emtricitabine/Tenofovir disoproxil Mylan will provide an information pack to doctors which covers the potential harmful effects of Emtricitabine/Tenofovir disoproxil Mylan on kidney function and information about use for pre-exposure prophylaxis.
Maltese: Il-kumpanija li tqiegħed lil Emtricitrabine/Tenofovir disoproxil Mylan fis-suq ser tipprovdi pakkett ta' informazzjoni lit-tobba li jkopri l-effetti potenzjali ta' ħsara ta' Emtricitabine/Tenofovir disoproxil Mylan fuq il-funzjoni tal-kliewi u informazzjoni dwar l-użu għall-profilassi ta' qabel l-esponiment.
English: How is Emtricitabine/Tenofovir disoproxil Mylan used?
Maltese: Emtricitabine/Tenofovir disoproxil Mylan?
English: Emtricitabine/Tenofovir disoproxil Mylan is also used to help prevent sexually transmitted HIV-1 infection in adults and adolescents who are at high risk of being infected (pre-exposure prophylaxis or PrEP).
Maltese: Emtricitabine/Tenofovir disoproxil Mylan jintuża wkoll biex jgħin fil-prevenzjoni tal-infezzjoni tal-HIV-1 trażmessa sesswalment f'adulti u f'adoloxxenti li jkunu f'riskju għoli li jiġu infettati (profilassi ta' qabel l-esponiment jew PrEP).
English: Emtricitabine/Tenofovir disoproxil Mylan (emtricitabine / tenofovir disoproxil)
Maltese: Emtricitabine/Tenofovir disoproxil Mylan fih żewġ sustanzi attivi l-emtriċitabina u t-tenofovir disoprossil.
English: For pre-exposure prophylaxis of HIV-1 infection, it is expected that Emtricitabine/Tenofovir disoproxil Mylan in the blood will stop the virus from multiplying and spreading from the site of infection in case the individual is exposed to the virus.
Maltese: Għall-profilassi ta' qabel l-esponiment tal-infezzjoni tal-HIV-1, huwa mistenni li Emtricitabine/Tenofovir disoproxil Mylan fid-demm se jwaqqaf il-virus milli jimmultiplika u jinfirex mis-sit tal-infezzjoni f'każ li lindividwu jkun espost għall-virus.
English: Because Emtricitabine/Tenofovir disoproxil Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Emtricitabine/Tenofovir disoproxil Mylan huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: Studies on the benefits and risks of the active substances in the authorised uses have already been carried out with the reference medicine, Truvada, and do not need to be repeated for Emtricitabine/Tenofovir disoproxil Mylan.
Maltese: Diġà saru studji dwar il-benefiċċji u r-riskji tas-sustanzi attivi fl-użi awtorizzati bil-mediċina ta' referenza, Truvada, u m'għandhomx għalfejn jiġu ripetuti għal Emtricitabine/Tenofovir disoproxil Mylan.
English: The company also carried out a study that showed that it is ‘bioequivalent' to the reference medicine.
Maltese: Il-kumpanija wettqet ukoll studju li wera li hija 'bijoekwivalenti' għall-mediċina ta' referenza.
English: Both emtricitabine and tenofovir work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected.
Maltese: Kemm l-emtriċitabina kif ukoll it-tenofovir jaħdmu b'mod simili billi jimblokkaw l-attività tattranskrittażi inversa, enzima prodotta mill-HIV li jħalliha timmultiplika lilha nnifisha fiċ-ċelloli li infettat.
English: For the treatment of HIV-infection, Emtricitabine/Tenofovir disoproxil Mylan, taken in combination with at least one other HIV medicine, reduces the amount of HIV in the blood and keeps it at a low level.
Maltese: Għall-kura ta' infezzjoni bl-HIV, Emtricitabine/Tenofovir disoproxil Mylan, meħud flimkien ma' minn talinqas mediċina waħda oħra kontra l-HIV, inaqqas l-ammont ta' HIV fid-demm u jżommu f'livell baxx.
English: Side effects reported with Emtricitabine/Tenofovir disoproxil Mylan are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Emtricitabine/Tenofovir disoproxil Mylan jiġu evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Emtricitabine/Tenofovir disoproxil Mylan has been shown to have comparable quality and to be bioequivalent to Truvada.
Maltese: L-Aġenzija Ewropea għall-Mediċini kkonkludiet li, b'mod konformi mar-rekwiżiti tal-UE, Emtricitabine/Tenofovir disoproxil Mylan intwera li għandu kwalità komparabbli u li huwa bijoekwivalenti għal Truvada.
English: What are the benefits and risks of Emtricitabine/Tenofovir disoproxil Mylan?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Emtricitabine/Tenofovir disoproxil Mylan?
English: Emtricitabine/Tenofovir disoproxil Mylan does not cure HIV infection or AIDS, but it holds off damage to the immune system and the development of infections and diseases associated with AIDS.
Maltese: Emtricitabine/Tenofovir disoproxil Mylan ma jfejjaqx l-infezzjoni tal-HIV jew l-AIDS, iżda jista' jittardja l-ħsara li ssir lis-sistema immunitarja u l-iżvilupp ta' infezzjonijiet u mard assoċjati mal-AIDS.
English: 67019 Scoppito (AQ) - Italy
Maltese: 67019 Scoppito (AQ) - L-Italja
English: Strada Statale 17, Km 22 67019 Scoppito (AQ) - Italy
Maltese: Statale 17, Km 22 67019 Scoppito (AQ) - L-Italja
English: Iscover contains lactose.
Maltese: Iscover fih lactose.
English: The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Maltese: Ir reazzjonijiet avversi klinikament rilevanti li ġew osservati fl-istudji CAPRIE, CURE, CLARITY, COMMIT u ACTIVE-A huma diskussi hawn taħt.
English: Iscover 300 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Iscover 300 mg
English: Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
Maltese: Purpura tromboċitopenika trombotika (TTP) (ara sezzjoni 4.4), anemija aplastika, panċitopenja, agranuloċitosi, tromboċitopenja severa, emofilja A akwiżita granuloċitopenja, anemija
English: PVC/PVDC/Aluminium blisters or all aluminium blisters in cardboard cartons containing 7, 14, 28, 30, 84, 90 and 100 film-coated tablets.
Maltese: Folji tal-PVC/PVDC/Aluminju jew folji kollha kemm huma ta' l-aluminju f'kaxxi tal-kartun li fihom 7, 14, 28, 30, 84, 90 u 100 pillola miksija b'rita.
English: Very rare, not known*
Maltese: Rari ħafna,mhux magħruf
English: Other medicines and Iscover
Maltese: Mediċini oħra u Iscover
English: Each film-coated tablet contains 12 mg of lactose and 13.2 mg of hydrogenated castor oil.
Maltese: Kull pillola miksija b'rita fiha 12 mg ta' lactose u 13.2 mg ta' castor oil idroġenat
English: België/Belgique/Belgien
Maltese: België/Belgique/Belgien Sanofi Belgium Tél/Tel:
English: Tablet core: mannitol (E421), hydrogenated castor oil, microcrystalline cellulose, macrogol 6000 and low-substituted hydroxypropylcellulose, Tablet coating: lactose monohydrate (milk sugar), hypromellose (E464), triacetin (E1518), red iron oxide (E172) and titanium dioxide (E171), Polishing agent: carnauba wax.
Maltese: macrogol 6000 u hydroxypropylcellulose b'sostituzzjoni baxxa Rita tal-pillola: lactose monohydrate (iz-zokkor li jinsab fil-ħalib), hypromellose (E464), triacetin (E1518), iron oxide aħmar (E172) u titanium dioxide (E171), Sustanza li tagħti l-lostru: carnauba wax.
English: The other ingredients are (see section 2 ‘Iscover contains lactose' and ‘Iscover contains hydrogenated castor oil'):
Maltese: Is-sustanzi l-oħra huma (ara sezzjoni 2 ‘Iscover fih il-lactose' u ‘Iscover fih il-castor oil idroġenat'):
English: Iscover 75 mg film-coated tablets Iscover 300 mg film-coated tablets
Maltese: Iscover 75 mg pilloli miksijin b'rita Iscover 300 mg pilloli miksijin b'rita
English: Iscover 75-mg film-coated tablets are round, biconvex, pink, engraved on one side with the number ‘75' and on the other side with the number ‘1171'.
Maltese: Il-pilloli miksija b'rita ta' Iscover 75-mg huma tondi, konvessi miż-żewġ naħat, ta' kulur roża, bin numru ‘75' imnaqqax fuq naħa waħda u n-numru ‘1171' imnaqqax fuq in-naħa l-oħra.
English: If Iscover is supplied in PVC/PVDC/aluminium blisters, store below 30°C.
Maltese: Jekk Iscover huwa fornut ġo folji tal-PVC/PVDC/Aluminju, aħżen f'temperatura taħt 30°C.
English: Iscover 300-mg film-coated tablets are oblong, pink, engraved on one side with the number ‘300' and on the other side with the number ‘1332'.
Maltese: Iscover 300 mg pilloli miksijin b'rita Roża, oblunga, b'«300» imnaqqax fuq naħa waħda u «1332» imnaqqax fuq in-naħa l-oħra.
English: Iscover 75 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Iscover 75 mg
English: Iscover is supplied in cardboard cartons containing 4x1, 10x1, 30x1 and 100x1 tablets in all aluminium perforated unit-dose blisters.
Maltese: Iscover huwa fornut f'kaxex tal-kartun li fihom 4x1, 10x1, 30x1 u 100x1 pilloli ġo folji mtaqqbin ta' doża waħda magħmulin kollha kemm huma mill-aluminju.
English: However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Maltese: Madankollu, pazjenti li daħlu fi studji kliniċi bi clopidogrel ngħataw varjeta` ta' prodotti mediċinali fl-istess ħin u dawn kienu jinkludu dijuretiċi, beta blockers ACEI, antagonisti tal-kalċju, sustanzi li jbaxxu l-kolesterol, vasodilataturi koronarji, sustanzi kontra d-dijabete (inkluża l-insulina), sustanzi antiepilettiċi, u antagonisti GPIIb/IIIa mingħajr ma kien hemm evidenza ta' interazzjonijiet avversi klinikament sinifikanti.
English: Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers.
Maltese: Konsistenti ma' dawn ir-riżultati, f'meta-analiżi li inkludiet 6 studji ta' 335 suġġett ikkurat b'clopidogrel f'livell fiss, ġie muri li l-espożizzjoni tal-metabolit attiv tnaqqas b'28% għallmetabolizzaturi intermedji, u 72% għall-metabolizzaturi dgħajfa filwaqt li l-inibizzjoni tal aggregazzjoni tal-plejtlits (5 μM ADP) tnaqqset b'differenzi fl-IPA ta' 5.9% u 21.4% rispettivament, meta mqabbel ma' metabolizzaturi estensivi.
English: Patients randomized in the ACTIVE program were those presenting with documented AF, i.e., either permanent AF or at least 2 episodes of intermittent AF in the past 6 months, and had at least one of the following risk factors: age ≥75 years or age 55 to 74 years and either diabetes mellitus requiring drug therapy, or documented previous MI or documented coronary artery disease; treated for systemic hypertension; prior stroke, transient ischaemic attack (TIA), or non-CNS systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; or documented peripheral vascular disease.
Maltese: riskju li ġejjin: età ≥ 75 sena jew età bejn 55 sa 74 sena u jew id-dijabete mellitus fejn ikun hemm ilbżonn tat-terapija bil-mediċini jew passat mediku ta' MI ddokumentat jew mard tal-arterji koronarji ddokumentat; ikkurat/a għall-ipertensjoni sistemika; passat mediku ta' puplesija, attakk iskemiku mhux permanenti (TIA) jew embolu sistemiku li ma jkunx fis-CNS; tnaqqis fil-funzjoni tal-ventriklu tax-xellug bil-porzjon tal-ħruġ mill-ventriklu tax-xellug < 45 %; jew mard vaskulari periferiku ddokumentat.
English: The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers.
Maltese: L-alleli CYP2C19*2 u CYP2C19*3 jgħoddu għall maġġoranza tal-alleli b'funzjoni mnaqqsa fil-Kawkasi u 99% f'metabolizzaturi dgħajfa Asjatiċi.
English: Iscover is supplied in cardboard cartons containing: 7, 14, 28, 30, 84, 90 and 100 tablets in PVC/PVDC/Aluminium blisters or in all aluminium blisters 50x1 tablets in PVC/PVDC/Aluminium blisters or in all aluminium perforated unit-dose blisters.
Maltese: - 7, 14, 28, 30, 84, 90 u 100 pilloli ġo folji tal-PVC/PVDC/Aluminju jew ġo folji magħmulin kollha mill-aluminju, - 50x1 pilloli f'folji tal-PVC/PVDC/Aluminju jew f'folji mtaqqbin b'doża waħda kollha kemm huma ta' l-aluminju.
English: The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8)
Maltese: inċidenza tad-dmija klinikament sinifikanti kienet simili għal dik osservata meta sustanzi trombolitiċi u heparin jingħataw flimkien ma' ASA (ara sezzjoni 4.8).
English: Coating:
Maltese: Iscover:
English: Fever
Maltese: fsada.
English: Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)*
Maltese: thienopyridines (bħal ticlopidine, prasugrel) (ara sezzjoni 4.4) )*, sindromu awtoimmunitarju talinsulina, li jista' jwassal għal ipogliċemija severa speċjalment f'pazjenti bis-sottotip HLA DRA4 (aktar frekwenti filpopolazzjoni
English: EU/1/98/070/001 - Cartons of 28 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/070/002 - Cartons of 50x1 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/070/003 - Cartons of 84 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/070/004 - Cartons of 100 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/070/005 - Cartons of 30 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/070/006 - Cartons of 90 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/070/007 - Cartons of 14 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/070/011 - Cartons of 7 film-coated tablets in PVC/PVDC/Alu blisters EU/1/98/070/013 - Cartons of 28 film-coated tablets in all aluminium blisters
Maltese: EU/1/98/070/001 - Kaxex ta' 28 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/98/070/002 - Kaxex ta' 50x1 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/98/070/003 - Kaxex ta' 84 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/98/070/004 - Kaxex ta' 100 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/98/070/005 - Kaxex ta' 30 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/98/070/006 - Kaxex ta' 90 pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/98/070/007 - Kaxex ta' 14-il pillola miksija b'rita fil-folji tal-PVC/PVDC/Alu EU/1/98/070/011 - Kaxex ta' 7 pilloli miksija b'rita fil-folji tal-PVC/PVDC/Alu
English: Pink, round, biconvex, engraved with «75» on one side and «1171» on the other side.
Maltese: Roża, tonda, konvessa miż-żewġ naħat, b' «75» imnaqqax fuq naħa waħda u «1171» imnaqqax fuq innaħa l-oħra.
English: The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Maltese: Il-metabolit attiv ta' clopidogrel jimpedixxi b'mod selettiv l-irbit ta' adenosine diphosphate (ADP) mar-riċettur tal-plejtlits P2Y12 u l-attivazzjoni suċċessiva talkumpless ta' glikoproteina GPIIb/IIIa bl-intervent ta' ADP, u b'hekk jimpedixxi l-aggregazzjoni tal plejtlits.
English: It is preferable not to take this product during pregnancy.
Maltese: Huwa preferibbli li ma tiħux dan il-prodott waqt it-tqala.
English: Other side effects include:
Maltese: Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-suq:
English: The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors).
Maltese: Il-benefiċċji osservati bi clopidogrel kienu indipendenti minn terapiji kardjovaskulari oħra akuti u fittul (bħall- heparin/LMWH, antagonisti ta' GPIIb/IIIa, prodotti mediċinali li jbaxxu l-lipidi,
English: - fluconazole or voriconazole, medicines to treat fungal infections, - efavirenz, or other anti-retroviral medicines (used to treat HIV infections), - carbamazepine, a medicine to treat some forms of epilepsy, - moclobemide, medicine to treat depression, - repaglinide, medicine to treat diabetes, - paclitaxel, medicine to treat cancer, - opioids: while you are treated with clopidogrel, you should inform your doctor before being prescribed any opioid (used to treat severe pain).
Maltese: - efavirenz, jew mediċini oħra antiretrovirali (użati għat-trattament tal-infezzjonijiet mill-HIV), - carbamazepine, mediċina għat-trattament ta' xi forom tal-epilessija, - moclobemide, mediċina għat-trattament tad-dipressjoni, - repaglinide, mediċina għat-trattament tad-dijabete, - paclitaxel, mediċina għat-trattament tal-kanċer,